Elin Hoffmann Dahl

Elin Hoffmann Dahl

Auto-generated profile, based on publicly available information

Elin Hoffmann Dahl

Medical Department, Haukeland University Hospital, Bergen, Norway

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2021 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
HHHamdan Mustafa Hamdan
Hamdan Mustafa Hamdan
LMLexson Mabrouk
Lexson Mabrouk
SMSultani Hadley Matendechero
Sultani Hadley Matendechero
TMTesfahun Bishaw Mengistie
Tesfahun Bishaw Mengistie
GAGabriel Alcoba
Gabriel Alcoba

11 January 2021 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
KMKnut Anders Mosevoll
Knut Anders Mosevoll
DCDana Cramariuc
Dana Cramariuc
CVChristian Alexander Vedeler
Christian Alexander Vedeler
BBBjørn Blomberg
Bjørn Blomberg
Here we present the case of a 37-year-old previously healthy man who developed fever, headache and a unilateral, painful neck swelling while working offshore. He had no known contact with anyone with COVID-19; however, due to the ongoing pandemic, a nasopharyngeal swab was performed, which was positive for the virus. After transfer to hospital for assessment his condition rapidly deteriorated, requiring admission to intensive care for COVID-19 myocarditis. One week after discharge he re-presented with unilateral facial nerve palsy. Our case highlights an atypical presentation of COVID-19 and the multifaceted clinical course of this still poorly understood disease.

14 March 2020 in Journal of Global Health
Verified
Journal Article
Open access
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
HZHassaan Zahid
Hassaan Zahid
KAKhawar Aslam
Khawar Aslam
WJWasim Jafri
Wasim Jafri

23 May 2022 in Oxford Medical Case Reports
Verified
Journal Article
Open access
PDF file
HZHassaan Zahid
Hassaan Zahid
KAKhawar Aslam
Khawar Aslam
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
WAWaqas Abbassi
Waqas Abbassi
SASuleiman Adan
Suleiman Adan
NLNasir Hassan Luck
Nasir Hassan Luck
Globally, 58 million people are living with hepatitis C virus (HCV) infection and 1.5 million new patients are infected every year. The advent of direct acting antivirals (DAAs) has revolutionized the treatment of HCV, opening the door to the ambitious World Health Organization HCV infection elimination strategy by 2030. However, emerging resistance to DAAs could jeopardize any hope of achieving these targets. We discuss a series of 18 patients within a resource-limited setting, who after failing standard sofosbuvir-daclatasvir-based regimen also failed to respond to advanced pan-genotypic treatment regimens, i.e. sofosbuvir-velpatasvir, sofosbuvir-velpatasvir-ribavirin and sofosbuvir-velpatasvir-voxilaprevir. To avoid the spread of refractory HCV strains within the existing epidemic, we call for increased attention and research regarding patients failing treatment on standard pan-genotypic regimens and the spread of HCV-resistant strains within the communities.

7 December 2021 in Tidsskrift for Den norske legeforening
Verified
Journal Article
Closed access
PDF file
EDElin Hoffmann Dahl
Elin Hoffmann Dahl
ITIda Tveter
Ida Tveter
07.12.2021: Debatt - Befolkningen i Norge mottar dose tre, mens leger og helsearbeidere i lavinntektsland er uvaksinerte.

1 April 2020 in The Lancet
Verified
Journal Article
Closed access
EDElin Hoffmann Dahl
Elin Hoffmann Dahl